Close Menu

NEW YORK (GenomeWeb News) – Monoclonal antibody company Affomix said today it has signed an agreement with Kalgene Pharmaceuticals to select antibodies with potential diagnostic and therapeutic use in breast cancer.

Under the agreement, Branford, Conn.-based Affomix will use its Y2HExpress technology to generate antibodies against several proprietary targets selected by Kalgene.

Financial terms of the agreement have not been disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.

An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.

US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.

In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.